1-2 of 2
Mario E Ojeda Uribe, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

Jacques Delaunay, Christian Recher, MD, PhD, Arnaud Pigneux, MD, PhD, Francis Witz, MD, Norbert Vey, MD, Odile Blanchet, Pascale Lefebvre, Isabelle Luquet, Isabelle Guillerme, Christelle Volteau, Emmanuel Gyan, MD, PhD, Bruno Lioure, Eric Jourdan, Didier Bouscary, MD, PhD, Romain Guieze, MD, Edouard Randriamalala, Mario E Ojeda Uribe, MD, Francois Dreyfus, Catherine Lacombe, Marie-christine Béné, Jean-Yves Cahn, MD, Jean-Luc Harousseau, MD, Norbert Ifrah
Journal: Blood
Blood (2011) 118 (21): 79.
https://doi.org/10.1182/blood.V118.21.79.79
Published: 2011
Journal Articles

Primary Prophylaxis against Invasive Fungal Infections (IFI) with Posaconazole (POS) or Voriconazole (VRC) Shows Better Efficacy Compared to No Systemic Prophylaxis during Induction and Consolidation Chemotherapy Cycles of Adult Acute Leukemia Patients

Mario E Ojeda Uribe, MD, Catherine Berg, Alain Gravet, Eric Sauleau, Dominique Bourderont, Celine Haby
Journal: Blood
Blood (2008) 112 (11): 4834.
https://doi.org/10.1182/blood.V112.11.4834.4834
Published: 2008